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Abstract: This paper discusses the need for interconnecting computational cancer models from different sources and scales within 
clinically relevant scenarios to increase the accuracy of the models and speed up their clinical adaptation, validation, and eventual 
translation. We briefly review current interoperability efforts drawing upon our experiences with the development of in silico models for 
predictive oncology within a number of European Commission Virtual Physiological Human initiative projects on cancer. A clinically 
relevant scenario, addressing brain tumor modeling that illustrates the need for coupling models from different sources and levels of 
complexity, is described. General approaches to enabling interoperability using XML-based markup languages for biological modeling 
are reviewed, concluding with a discussion on efforts towards developing cancer-specific XML markup to couple multiple component 
models for predictive in silico oncology.
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Introduction
The last few decades have witnessed an increased 
interest of the scientific community in the development 
of computational models for simulating tumor growth 
and  response  to  treatment.1–8  The  major  modeling 
techniques  can  be  differentiated  as  predominantly 
continuous  and  predominantly  discrete  models. 
Continuous  models  rely  primarily  on  differential 
equations to describe processes such as diffusion of 
molecules, changes in tumor cell density, and invasion 
of tumor cells into the surrounding tissue.9–14 Discrete 
modeling considers several discrete states in which 
cells may be found and possible transitions between 
them  governed  by  “decision  calculators”  such  as 
cytokinetic diagrams and agent-based techniques.15–20 
Discrete models are usually represented by cellular 
automata of several forms and variable complexity. 
Due  to  the  hypercomplexity21  of  cancer-related 
topics, each modeling approach is intrinsically able 
to satisfactorily address only some of the aspects of 
this multifaceted problem.
In  recent  years,  data-driven  computational 
cancer  modeling  has  become  an  active  field 
in cancer research.22 In particular, the development 
of cancer models that encompass different biological 
scales in time and space (ie, multiscale cancer models) 
has gained attention in view of the potential to integrate 
disparate kinds of patient data and to enable patient-
specific prediction and assist in treatment planning.23–25 
Consequently,  these  techniques  fall  into  two  basic 
types of approaches to cancer modeling: “bottom-up” 
and “top-down.” The bottom-up approach studies the 
components of a system individually and then integrates 
the properties and functions of each component to make 
predictions about the behavior of the entire system.26 
On the other hand, a top-down approach, driven by 
observed  biological  characteristics  or  phenomena, 
builds up theories that would explain the observed 
behavior.26 In the particular case of cancer simulation 
and  prediction,  agent-based  modeling  (ABM)  has 
been  widely  adopted  as  a  useful  technique  for 
developing bottom-up models, whereas both discrete 
and continuum modeling are used for developing top-
down  models.  Combining  both  techniques  yields  a 
“hybrid” approach.
The bottom-up approach is suitable for simulating 
emergent  cancer  behaviors  resulting  from  cell-cell 
and cell-host interactions and intracellular signaling 
of individual cells. Many bottom-up multiscale cancer 
models have been developed so far where most of 
them are based on the ABM technique and incorporate 
a  specific  molecular-level  description.  Recent 
representative  examples  include  those  quantifying 
the relationship between extracellular growth factors 
and multicellular cancer growth and expansion,27–30 
those investigating cancer cell motility in an evolving 
tumor  population  by  connecting  gene  regulatory 
networks  to  cell  phenotypes,31–33  those  describing 
genotype-phenotype relations based on and studying 
the  effects  of  different  cell  adhesion  pathways  on 
cancer  cell  invasion  patterns.34,35 All  these  models 
explicitly access and draw on prior knowledge about 
biochemical  and  biophysical  mechanisms  and  the 
underlying  biological  properties  of  cancer.  This 
demonstrates the potential of the bottom-up approach 
in making full use of the sizeable amount of molecular 
and microscopic data being generated experimentally 
and in clinics. A top-down simulation approach15,36,37 
typically starts from the macroscopic imaging data 
(a  high  biocomplexity  level)  and  proceeds  toward 
lower biocomplexity levels. When there is a need for 
an upward movement in the biocomplexity scales, 
a summary of the available information pertaining 
to  the  previous  lower  level  is  used.  A  top-down 
approach is suitable for directly simulating clinical 
trials,  and  therefore  clinically  adapting,  validating, 
and  eventually  translating  the  models  into  clinical 
practice. It also offers the possibility to exploit the 
actual  multiscale  data  of  the  individual  patient, 
including molecular markers.
To better understand and subsequently treat cancer 
more effectively, a significant effort is underway to 
develop and use models of cancer pathophysiology 
in order to simulate cancer evolution and promote 
individualized, that is, patient-specific optimization 
of, disease treatment. The latter is leading to a central 
clinical  question  from  the  context  of  predictive 
oncology: Is  it possible to  select the best targeted 
therapy for a patient by computer simulation?
To answer this question and be able to promote 
predictive oncology, it is mandatory to validate cancer 
models in real clinical cases and assess the added value 
in  optimizing  therapy  selection  for  the  individual 
patient in studies. It is important to keep in mind that 
cancer is a multiscale phenomenon, and while many 
research  groups  develop  significant  models,  they Diversity in computational cancer modeling
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usually address only specific scales (from molecular 
to tissue level) and are difficult to integrate due to the 
fact that there is no universally accepted standard for 
presenting and implementing such models. Another 
adverse effect of such compartmentalized research is 
that there is no established protocol for the clinical 
validation of cancer models or for the assessment of 
their results. In particular, the lack of standardized 
descriptions  of  models  significantly  hampers  their 
widespread adoption and clinical testing and, more 
importantly, their interconnection in order to efficiently 
couple models of different scales and improve their 
accuracy.
This paper draws on our experiences with the VPH38 
(Virtual Physiological Human, http://www.vph-noe.
eu) projects on cancer modeling: ACGT39 (Advancing 
Clinico  Genomic  Trials  on  Cancer,  eu-acgt.org), 
ContraCancrum6  (Clinically  Oriented  Cancer 
Multilevel modelling, http://www.contracancrum.eu) 
and the US CViT40 (Center for the Development of a 
Virtual Tumor, http://www.cvit.org) projects. We also 
look to the future with the developments within the 
TUMOR41 (Transatlantic Tumor Model Repositories, 
http://www.tumour-project.eu) project that is paving 
the way for an integrated, interoperable transatlantic 
research  environment  and  investigating  standards 
for simulation and modeling within the domain of 
predictive in silico oncology.
clinically Oriented in silico Oncology
Sophisticated  multiscale  models  yield  valuable 
quantitative  insights  into  complex  mechanisms 
involved in cancer and may ultimately contribute to 
patient-specific  therapy  optimization.  The  ultimate 
goal of clinically oriented cancer simulation models is 
their eventual translation into clinical practice, which 
entails  two  key  steps.  Firstly,  thorough  sensitivity 
analyses are carried out in order to both comprehend 
and  validate  model  behaviors.  This  will  enable 
researchers to gain further insights into the simulated 
mechanisms in a more quantitative way. Secondly, 
an adaptation and validation process based on real 
clinical data is carried out.
The  clinical  orientation  of  a  model  constitutes 
a  fundamental  guiding  principle  throughout  its 
development. In order to ultimately support clinical 
decision making in a patient-individualized manner, 
clinically oriented models should be under continuous 
refinement within the framework of clinical trials. For 
a clinician it is important that the in silico experiments 
can address and answer precisely for each patient the 
following questions: What is the natural course of the 
tumor growth over time in size and shape? When and 
where to is the tumor metastasizing? Can the response 
of  the  local  tumor  and  the  metastases  to  a  given 
treatment be predicted in size and shape over time? 
What is the best treatment schedule in terms of drugs, 
surgery, irradiation, and their combination, dosage, 
time  schedule  and  duration  to  achieve  a  positive 
outcome?  Is  it  possible  to  predict  severe  adverse 
events of a treatment and to propose alternatives to 
them without jeopardizing the outcome? Is it possible 
to predict a cancer before it occurs and to recommend 
treatment  options  to  prevent  the  occurrence  or  a 
recurrence? The question to be addressed would be 
decided by the clinician and consequently influence 
the  model.  Clinically  oriented  in  silico  oncology 
seeks to address such questions.
An example clinical scenario
To exemplify the need for coupling models together 
for  clinically-oriented  in  silico  oncology,  in  this 
section we describe a clinical scenario that combines 
two  distinctly  different  approaches  for  different 
purposes to increase the accuracy of a diagnosis.
Malignant  gliomas  (World  Health  Organization 
[WHO] grade III and IV) are progressive brain tumors 
that can be divided into anaplastic gliomas (WHO 
grade  III)  and  glioblastoma  multiforme  (GBM) 
(WHO grade IV) based upon their histopathologic 
features.42,43 Magnetic resonance imaging (MRI) has 
become the method of choice in the diagnostic workup 
of  these  patients.44  Because  of  edema  surrounding 
the  tumor  and  the  presence  of  necrotic  and  vital 
areas within the tumor, the exact tumor volume is 
nearly impossible to define.45 This is true at the time 
of diagnosis and even much more enhanced during 
treatment, as edema and necrotic areas might change 
with an increase in tumor volume despite treatment 
response (pseudoprogression).
Magnetic  resonance  spectroscopy,  diffusion 
weighted  imaging,  as  well  as  perfusion  MRI,  can 
depict changes in the cellular metabolism. Positron 
emission tomography is used to detect tumors with 
high  metabolic  rates  of  glucose.  These  commonly 
used  imaging  modalities  still  pose  problems  when Johnson et al
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identifying pseudoprogression and pseudoregression 
in clinical practice. On average, patients who suffer 
from grade III gliomas have an average survival of 
2 to 3 years. In contrast, most patients with GBM die of 
the disease within a year following diagnosis.42,46 Over 
the last few years the most important improvement 
has been achieved by the concomitant and adjuvant 
application of temozolomide and radiotherapy, which 
increased  the  survival  period  from  approximately 
12  to  15  months.47  Long-term  survivors  for  more 
than 5 years are sparse (3%–5% of GBM patients).48 
Improvement in outcome of patients with GBM is 
urgently needed and can only be achieved through a 
combined effort between clinicians, basic researchers, 
computer scientists, mathematicians, and legal and 
ethical  policy-makers.  New  treatment  modalities 
need to be developed.
The  simulation  of  GBM  in  silico  is  one  such 
option by modeling tumor growth and response to 
treatment. Since cancer is a strongly multiscale natural 
phenomenon,  in  order  to  be  able  to  provide 
reliable  predictions  of  its  spatiotemporal  course, 
including response to treatment modalities, several 
biocomplexity scales should be addressed concurrently 
in a combinatorial way. This implies that sufficiently 
advanced  models  of  several  biomechanisms 
concerning  different  spatiotemporal  scales  have  to 
be  developed  and  adequately  coupled.  Different 
modeling groups worldwide focus on different scales 
and  contexts  of  tumor  dynamics.  Therefore,  the 
models they produce have in general different external   
and internal structures. Coupling such models tends 
to be a highly demanding task. The combination of a 
bottom-up approach with a top-down approach will 
combine data from systems biology such as cell cycle 
duration or methylation status of MGMT (a DNA repair 
gene correlating with  outcome after temozolomide 
treatment49) or deregulated metabolic pathways with 
real patient data such as age, appearance of the tumor 
in imaging studies, and outcome. As a goal for the 
future, such spatiotemporal multidimensional models 
have to be integrated into daily clinical care and need 
to provide validated results for single patients in due 
time. Clinicians using such models should be guided 
by a closed workflow that encapsulates patient data 
provision, preprocessing and postprocessing of data 
(including  anonymization  or  pseudonymization  of 
patient-identifiable data), uploading and integration 
of data, and computational execution of the chosen 
in  silico  model.  The  validated  results  after  model 
execution  are  then  sent  to  the  clinician  to  assist 
in  the  treatment  decision-making  process.  For 
example, consider the following possible models of 
treatment response in GBM that may be calculated 
computationally:  (1)  Differentiation  between  real 
progression and pseudoprogression after irradiation 
of  the  tumor  and  (2)  Simulation  of  the  response 
to  a  combined  treatment  with  irradiation  and 
temozolomide.
The  correct  assessment  of  response  to  a  given 
treatment  is  difficult  to  assess.  An  unspecific 
disruption  of  the  blood-brain  barrier  may  cause  a 
reactive  treatment-related  edema  mimicking  tumor 
progression.44  This  is  often  seen  after  irradiation 
and summarized as pseudoprogression. On the other 
hand,  pseudoregression  is  also  found  if  treatment 
(eg, antiangiogenic drugs) is not affecting the tumor 
itself but the surrounding edema.50 While a predictive 
simulation  of  treatment  response  in  the  second 
model  provides  a  means  to  assisting  therapy,  the 
differentiation of real and pseudo responses, as in the 
first model, could be integrated. These two models 
coupled together might increase the accuracy of an in 
silico prediction of GBM treatment response.51
An Overview of Major 
Interoperability efforts
The  need  for  coupling  models  together  has  been 
highlighted by the clinical scenario described in the 
previous section, but how can we facilitate connecting 
disparate  models  together?  Markup  languages  for 
modeling biological systems (based on the Extensible 
Markup Language [XML]52,53) emerged in the early 
2000s to address the problems associated with the 
lack of standards for describing biological models. 
Four  major  languages  have  gained  prominence 
in  recent  years  each  of  which  aims  to  tackle  the 
problems associated with interoperability of models. 
The  markup  languages  discussed  here  are  SBML, 
CellML, FieldML and insilicoML.
Systems biology markup language
The Systems Biology Markup Language, commonly 
referred to as SBML, is a domain-specific markup 
language  that  addresses  biochemical  processes 
at  the  molecular  scale.54,55  The  motivations  for Diversity in computational cancer modeling
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SBML  were  3-fold:  (1)  to  support  multiple  tools 
with  a  single  common  file  format,  (2)  to  enable 
repeatability of experiments with published models 
irrespective  of  modeling  software  platform,  and 
(3) to promote longevity of published models beyond 
the lifetime of current modeling tools. These aims 
are quite generalized; however, the authors explain 
that SBML does not aim to be a generic modeling 
language to cover all types of quantitative models. 
They recognize that the de facto understanding of 
different biological concepts evolve, and, as such, they 
submit that a modeling language for systems biology 
be domain-specific and is structured to represent the 
consensus of current understanding in the field. This 
aims to enable the state-of-the-art modeling tools in 
systems biology to use a common language in which 
to communicate models rather than having a single 
generic  modeling  language  for  biological  and/or 
computational modeling.
To describe the mathematical components in SBML, 
the  language  utilizes  Content  MathML,  an  XML 
language  for  describing  mathematical  formulae.56 
Typically,  the  mathematics  used  to  model  systems 
biology is in the form of declarative formulae such 
as ordinary differential equations (ODEs) and partial 
differential equations (PDEs), and the markup used 
can adequately describe such equations. Models are 
structured as sets of components termed compartments 
that  broadly  represent  containers  for  chemical 
substances. Changes in the values and states within 
compartments are dictated by description statements 
of biochemical transformations or transport. It also 
provides  the  facility  to  associate  metadata  with 
models in order to properly curate them within online 
databases. The details of the latest release of SBML 
(Level 3) are extensively described in Hucka et al.55
CellmL
Developed  out  of  the  physiological  modeling 
community, CellML is a modeling markup language 
that aims to cover a range of biological phenomenon, 
primarily cell function.57,58 CellML was developed to 
address the lack of standards for describing cellular 
function and to provide unambiguous representations 
of models. The authors identified that because of the 
lack of rigor and standards in the publishing process, 
models  could  not  be  easily  validated.  Errors  are 
commonly  introduced  when  publishing  models  in 
journal texts, and computational implementations are 
commonly targeted at specific software frameworks 
and tools, making the models themselves less portable. 
This poses problems when sharing with researchers 
who are unfamiliar with the modeling methodologies, 
frameworks, and tools others may have used.
Like  SBML,  CellML  utilizes  Content  MathML 
to  describe  systems  modeled  using  mathematical 
equations. CellML is designed to be modular in that 
encapsulated  models  (possibly  of  different  scales) 
can  be  linked  together  through  public  and  private 
interfaces.  This  allows  multiple  models  whose 
variables might refer to the same entity can be logically 
linked. This component-based approach allows reuse 
of whole models or parts of models described with 
CellML markup. To compliment CellML’s functional 
description  of  biological  cells,  FieldML  is  being 
developed as a language for modeling physiological 
structures  based  on  geometric  meshes  and  fields, 
allowing the representation of spatial variation and 
PDEs.59  Structures  are  represented  as  abstractions 
of  physical  states  over  locations  described  and 
approximated sets of functions.
insilicomL
insilicoML (ISML) is a markup language for describing 
biological  models  developed  out  of  the  Japanese 
Physiome  Project.60–62  ISML  was  developed  to  be 
a modular description of models and has a number 
of similarities to CellML. The authors designed the 
language with a set of tools that facilitate conversion 
to multiple representational formats such as CellML, 
SBML,  general-purpose  source  code  (C++),  and 
document markup (LaTeX). ISML supports a range 
of mathematical models such as those described with 
ODEs and PDEs as well as ABM-based models that 
utilize descriptions of conditional behavior.
ISML  models  a  system  as  an  aggregate  set 
of  modules  corresponding  to  entities  each  with 
a  state  and  corresponding  implementation.  The 
implementation  details  how  the  states  change  in 
reaction to specific events and to the progression of 
time and, like CellML and SBML, can be modeled 
mathematically.  Graph-like  edges  linking  input/
output nodes of modules, termed ports, are used for 
signaling  and  communication  between  modules. 
These edges enable the communication of physical 
quantities representing different values of a module’s Johnson et al
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internal state. By structuring biological models in this 
way, models can be constructed from components as 
graphs and hierarchies and represented as independent 
modules.  Modules  in  ISML  are  conceptualized 
as  capsules  (the  authors  term  this  “capsulation”). 
Calpsulation is where multiple capsules are grouped 
and  linked  together,  packaging  them  into  a  larger 
capsule module. Capsules, like other modules, also 
possess input and output ports to allow aggregates 
to  be  composed  of  other  aggregates.  To  create 
logical  connections  between  capsules  ports  with 
the encapsulated internal modules, a special case of 
edge, termed a “forwarding edge,” links capsule ports 
with internal module ports. Capsulation can lead to 
the  composition  of  hierarchical  representations  of 
models.
A  number  of  similarities  exist  between  ISML 
and  CellML.  For  example,  the  concepts  of  ISML 
modules  and  physical  quantities  map  to  CellML’s 
components  and  variables  respectively.  However, 
these parallels are not exhaustive. Although CellML 
connections  between  public  and  private  model 
interfaces  are  structurally  similar  to  ISML’s  edges 
and ports, respectively, in CellML connections link 
entity variables that are semantically equivalent but 
do not model any directionality. ISML edges have 
explicit direction from input ports to output ports. 
Additionally, ISML edges can have operational types 
attached to them by labeling each edge with a verb or 
verb phrase describing a functional relationship. ISML 
modules also have a defined type such as functional 
unit, container, capsule, or template. The definitions 
of each ISML module type are not discussed in this 
paper but are described in full in a series of papers by 
the original authors.60–62
Discussion
Each of the markup languages reviewed approaches 
modeling different aspects of biology in a generalized 
fashion.  However,  we  do  not  believe  that  such 
a  generic  approach  to  modeling  is  appropriate 
when  considering  more  complex,  wide-ranging 
phenomenon and multiscale behaviors considered in 
the current cancer modeling literature. Typically, these 
state-of-the-art markup languages take a declarative 
mathematical  approach  to  modeling,  where  the 
biological simulations are derived by mathematical 
formulae being fed into numerical solvers. They all 
use MathML for functional and behavioral description, 
and, while MathML is a mature markup language, 
it  does  not  provide  any  constructs  for  describing 
logic and control flow or complex data structures. 
Models based on markup using MathML are typically 
simulated  through  solving  ODEs  and  differential 
algebraic  equations.  Control  flow  constructs  and 
domain-specific  components  will  give  a  biological 
modeling markup language more expressive power, 
especially where models are developed using an in 
silico methodology rather than a purely declarative 
mathematical approach.63 For example, algorithmic 
and cellular automata-based cancer models cannot be 
expressed in any of the currently available markup 
languages, let alone any hybrid top-down–bottom-up 
composite models.
The  generic  application  target  of  these  markup 
languages  is  also  a  barrier  to  their  adoption  and 
usage for cancer modeling. SBML is a specialized 
language that describes molecular components and 
their relationships with each other. CellML expresses 
models as declarative mathematics that is processed 
by numerical solvers, mainly to model cell function, 
and the domain concepts in CellML are decoupled 
from the language as metadata annotations. FieldML 
adds the spatial description element to compliment 
CellML models, but it is however limited to continuous 
models of behaviour, being unable to represent the 
discrete ABM approaches. ISML is similar to CellML 
in its application to a wide range of biology, and also 
demonstrates multiscale application, but again in a 
very generic fashion.
SBML Level 3 supports modular linking of models 
through  hierarchical  model  composition.  A  model 
definition might contain several submodel instances 
each as part of a composite model. “Ports” are used to 
act as interfaces to internal elements of a SBML model; 
however, these are optional. In practice, submodels 
declared with model definitions embedded within the 
same document allow direct access to other submodel 
internal  details.  Although  the  use  of  ports  was 
introduced to define abstract interfaces, they do not 
enforce any sort of encapsulation ultimately leading 
to content coupling. CellML version 1.1 is designed 
to be modular in that encapsulated models can be 
linked together through public and private interfaces. 
This allows multiple models whose variables might 
refer  to  the  same  entity  to  be  logically  linked. Diversity in computational cancer modeling
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This  component-based  approach  allows  reuse  of 
whole  models  or  parts  of  models  described  with 
CellML  markup.  This  modular  coupling  has  been 
demonstrated  in  a  number  of  published  models; 
however, it is not without its problems. Variables can 
be made directly accessible by declaring them to be so 
through public interfaces leading to content coupling. 
Both  SBML  and  CellML  encapsulate  models  and 
internal  components  to  a  certain  degree,  but  their 
approaches  look  to  relatively  basic  solutions  to 
ensure backwards compatibility for existing models. 
What neither language takes into account is that by 
simply allowing direct connectivity of data between 
modules, any notion of cohesion is not accounted for. 
Models typically simulate multiple processes where 
biological  concepts  may  be  spread  over  different 
parts of the code or multiple concepts represented in 
one portion of code. A smarter approach to grouping 
concerns is needed to achieve true modularity and 
encapsulation.
To address the specific domain of cancer modeling, 
we  are  actively  involved  with  the  development 
of  a  markup  language,  TumorML,  to  describe 
computational models within the TUMOR project. 
The motivation for such a markup language is 2-fold: 
(1) to describe the implementation of these cancer 
models in an abstract manner that is not tied to any 
particular programming notation and (2) to be able 
to couple our models64 to address cases such as the 
GBM  scenario  described  earlier.  The  challenges 
posed in developing TumorML include formalizing 
cancer terminology, linking biological entities with 
computational and mathematical elements of models, 
and  incorporating  features  to  allow  for  curating 
models in online repositories.
Initially  we  have  developed  a  vocabulary  that 
includes metadata for curation (reusing the Dublin 
Core Metadata Element Set (http://www.dublincore.
org) combined with our own cancer-specific metadata) 
and for describing the public interfaces with existing 
models that have been developed and published as 
source  code  and  executable  files,  the  groundwork 
of which has been described by Johnson et al.65 This 
will allow us to investigate how to couple models 
of  different  scales  together  through  their  exposed 
parametric inputs and outputs; an initial “black box” 
approach  to  computational  model  execution  and 
coupling.  Portions  of  the  Job  Description  Markup 
Language66 are reused to facilitate the specification 
of  the  underlying  computational  requirements 
for  executing  computational  models.  Parametric 
interfaces  are  described  as  named  variables  with 
unit  and  quantity  metadata  annotations.  These 
computational  interfaces  could  then  be  mapped  to 
biological  terminology  ultimately  providing  a  way 
to more easily validate the cancer biology through 
correct  semantic  matching,  but  also  to  provide  a 
means  to  enforce  type  and  units  checking  where 
heterogeneities in model descriptions exist.
Domain-specific markup, such as TumorML, could 
be used to assist in the coupling models of different 
scales that may have very distinct concerns. If we 
consider our earlier GBM scenario, our first model 
is solely concerned with differentiating between real 
and pseudo progression and regression of a tumor 
after  radiotherapy.  This  might  be  calculated  by 
analyzing a patient’s MRI scans at the macroscopic 
scale.  Our  second  model  concerns  simulation  of 
predicted  tumor  growth  after  a  combination  of 
therapies, perhaps looking at cell-cell interactions 
in tissue at the microscopic scale based on a wide 
range of patient data in combination with initial MRI 
scans.  Treating  model  implementations  as  black 
boxes, exposed only through a declared interface, 
in  combination  with  metadata  relating  to  how  to 
run a model, may allow compound models to be 
constructed via markup.
The  cancer  modeling  community  is  adopting 
TumorML for publishing existing models, beginning 
with efforts in TUMOR and related projects, and we 
are working with modelers to develop the next level 
of more detailed abstractions of the inner workings 
of models, such as work on embedding functional 
domain-specific code (for vascular tumor growth) 
into TumorML documents.67 Significant effort might 
be required to port existing models to TumorML, so 
by providing multiple levels of abstractive notation 
in  our  markup  we  can  wrap  existing  models  in 
early versions of TumorML as well as develop new 
models  with  an  evolving  markup  specification. 
Experimental and clinically oriented vocabularies 
or ontologies, such as the Simulation Experiment 
Description  Markup  Language  (SED-ML)68  and 
the  CancerGrid  model  ontology,69  could  also  be 
integrated to assist in management of clinical trials 
of TumorML models.Johnson et al
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conclusion
Predictive in silico oncology is an evolving field of 
study,  and,  with  an  increasing  number  of  models 
being developed by a growing research community, 
standards need to be adopted to facilitate model sharing 
and interoperability. Modeling cancer is approached 
from two distinct angles: bottom-up, from a finer-level 
molecular  modeling  detail  to  simulate  higher-level 
observed behaviors, and top-down, where models are 
actually based on macroscopic observed behavior. The 
two types of techniques can be combined to possibly 
increase  the  accuracy  of  clinically  relevant  models 
such as those exploited by the VPH projects (ACGT, 
ContraCancrum)  and  CViT.  An  ability  to  couple 
models of different scales and approaches is needed, 
as illustrated by the GBM scenario described in this 
paper, where the combination of models to differentiate 
between  real  progression  and  pseudoprogression  in 
response  to  treatment  and  the  simulation  of  tumor 
growth with and without treatment is just one possible 
example of how one might increase the accuracy of 
using such computational cancer models in predictive 
oncology. The currently available markup languages 
reviewed each have their own merits; however, each 
also has its own pitfalls when applied to the cancer-
modeling domain. SBML is specific to the domain of 
systems biology, FieldML, to physiological structures, 
while  CellML  and  ISML  are  too  generalized  and 
lack the domain-specific descriptive power required 
in cancer modeling. TumorML is being developed to 
address the need for a standardized domain-specific 
multiscale cancer markup language, where the existing 
state-of-the-art alternatives fall short. The combination 
of  existing  cancer  ontologies  with  existing  markup 
vocabularies  will  lead  to  the  facilitation  of  model 
coupling, ultimately leading to the possibility of better, 
more accurate in silico models that move one step closer 
to clinical translation and use in predictive oncology.
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